



Healthcare Headline Transactions

	Target	Acquiror	Acquisition Synopsis
Medical Devices	PARAGARD Intrauterine Device Business	©operSurgical	 CooperSurgical Inc. entered into a definitive asset purchase agreement to acquire global rights and business of PARAGARD Intrauterine Device from Teva Women's Health, Inc. for \$1.1 billion Teva Women's Health, Inc. develops and markets pharmaceutical products for women CooperSurgical Inc. develops medical instruments, devices, and disposables with a focus on women's health care and minimally invasive surgery Implied Enterprise Value Multiples: 6.5x Revenue
Medical Devices	<u>neotract</u>	Teleflex ®	 Teleflex Urology Limited entered into a definitive agreement to acquire NeoTract, Inc. for \$1.1 billion, including a \$725 million in upfront payment and up to \$375 million upon achievement of milestones NeoTract, Inc. develops and manufactures minimally invasive medical devices that address unmet needs in the field of urology Teleflex Urology Limited manufactures medical imaging equipment Implied Enterprise Value Multiples: 21.6x Revenue
Healthcare Services	COOK [*] GROUP Cook Pharmica Business	Catalent,	 Catalent Pharma Solutions, Inc. entered into an interest purchase agreement to acquire Cook Pharmica LLC from Cook Group Incorporated for \$950 million Cook Pharmica LLC provides contract development and manufacturing services to pharmaceutical and biopharmaceutical companies Catalent Pharma Solutions, Inc. provides development solutions and delivery technologies Implied Enterprise Value Multiples: 5.3x Revenue
Healthcare Services	LANDAUER®		 Fortive Corporation (NYSE:FTV) entered into a definitive agreement to acquire Landauer, Inc. (NYSE:LDR) for \$770 million, a 9% premium Landauer, Inc. provides technical and analytical, and outsourced medical physics services Fortive Corporation designs, develops, manufactures, markets, and services professional and engineered products, software, and services Implied Enterprise Value Multiples: 4.8x Revenue, 17.0x EBITDA


Note: All premium data calculated based on the closing market value one day prior to announcement






Enterprise Value / LTM EBITDA 25.0x 22.4x EV / LTM EBITDA 20.0x 18.2x 18.3x 14.7x 15.0x 10.0x 5.0x 0.0 BioTech / Healthcare Life Sciences Medical Pharma Services / Diagnostics Devices

LTM Gross & EBITDA Margins



LTM Stock Price Index



Healthcare Services Medical Devices Life Sciences / Diagnostics Biotech / Pharma S&P 500

Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17

Selected Bi	otechnology /	Pharmaceutical Transactions	Selected Healthcare Services Transactions			
Target	Acquiror	Target Description	Target	Acquiror	Target Description	
Rigontec GmbH	Merck & Co., Inc.	Rigontec GmbH is a biopharmaceutical company that develops RNA-based immunotherapeutics Transaction Value: \$137 million upfront and \$417 million in milestones	Therapure Biopharma Inc., (CDM Business)	3SBio Inc.; CITIC Private Equity Funds Management Co., Ltd.; and other	Therapure Biopharma Inc., Contract Development and Manufacturing Business, provides contract development and manufacturing services Transaction Value: \$298 million	
Dimension Therapeutics, Inc.	Ultragenyx Pharmaceutical Inc.	Dimension Therapeutics, Inc. focuses on discovering and developing therapeutic products Transaction Value: \$153 million	inviCRO, LLC	Konica Minolta, Inc.	inviCRO, LLC provides a suite of services and software for medical imaging analysis Transaction Value: \$285 million	
WellSpring Pharmaceutical Corporation	Audax Group, Inc.; Audax Private Equity Fund V LP	WellSpring Pharmaceutical Corporation manufactures, markets, and distributes prescription and over-the-counter medicines	SpecialtyCare, Inc.	Kohlberg & Company, L.L.C.	SpecialtyCare, Inc. provides outsourced clinical services for hospitals and other healthcare providers	

Selected Life Sciences / Diagnostics Transactions

Target	Acquiror	Target Description	Target	Acquiror	Target Description
BioView Ltd.	Beijing Beilu Pharmaceutical Co.,Ltd	BioView Ltd. develops, manufactures, and markets automated cell imaging and analysis solutions Transaction Value: \$22 million	Argon Medical Devices, Inc.	Weigao International Medical Hong Kong Limited	Argon Medical Devices, Inc. manufactures and sells medical devices for interventional radiology, vascular surgery, cardiology, and other Transaction Value: \$850 million
Shiel Medical Laboratory, Inc.	Quest Diagnostics Incorporated	Shiel Medical Laboratory, Inc. provides clinical laboratory testing services in the field of medical diagnostics	Bird and Cronin, Inc.	Dynatronics Corporation	Bird and Cronin, Inc. manufactures orthopedic soft goods, sports medicine related items, and specialty patient care products Transaction Value: \$16 million
Trevigen, Inc.	Bio-Techne Corporation	Trevigen, Inc. manufactures and develops products and technologies for cancer research, drug discovery, genetic toxicology, regenerative medicine, and stem cell work	G&H Wire Company, Inc.	Altaris Capital Partners, LLC	G&H Wire Company, Inc., doing business as G&H Orthodontics, manufactures and supplies clinical solutions for the orthodontic community

Recent TM Capital Healthcare Transactions





James I. McLaren Managing Director jmclaren@tmcapital.com 212.809.1414



TM Capital Contacts

Selected Medical Device Transactions

Michael S. Goldman Managing Director mgoldman@tmcapital.com 212.809.1419



Paul R. Smolevitz Managing Director psmolevitz@tmcapital.com 212.809.1416

TM Capital Corp. is a partner-owned investment banking firm based in New York, Boston and Atlanta, which has completed over 300 transactions with a combined value in excess of \$20 billion. Since 1989, we have advised clients navigating a full range of critical transactions, including complex mergers, acquisitions, debt and equity financings, minority and majority recapitalizations, restructurings, and advisory services including takeover defense, fairness and solvency opinions and valuations. We have built deep industry expertise in key sectors and our team regularly publishes research highlighting current and emerging trends in targeted industries and markets. TM Capital is a member firm of Oaklins, the world's most experienced mid-market M&A advisor with over 700 M&A professionals in over 60 offices operating in the major financial centers in the world. Members have closed over 1,500 transactions totaling more than \$75 billion in value over the past five years.

New York 641 Lexington Ave 30th Floor New York, NY 10022 **Boston** 201 Washington St 32nd Floor Boston, MA 02108 **Atlanta** 1230 Peachtree Rd NE Suite 550 Atlanta, GA 30309



www.tmcapital.com